Hjem › Neuroendokrin karcinom
Neuroendokrin karcinom kliniske forsøg rekrutterer i USA
16 studier for Neuroendokrin karcinom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Houston, TX6 studier
- New York City, NY6 studier
- Arlington, VA5 studier
- Dallas, TX4 studier
- Los Angeles, CA4 studier
- Washington, DC4 studier
- New Haven, CT3 studier
- Seattle, WA3 studier
- Columbus, OH3 studier
- Atlanta, GA3 studier
- Nashville, TN3 studier
- Grand Rapids, MI3 studier
- Denver, CO3 studier
- St. Louis, MO3 studier
Efter delstat
- Californien6 studier
- Colorado4 studier
- Connecticut3 studier
- Florida5 studier
- Georgia4 studier
- Louisiana3 studier
- Maryland6 studier
- Michigan3 studier
- Missouri3 studier
- New Jersey4 studier
- New York6 studier
- Ohio4 studier
- Tennessee4 studier
- Texas8 studier
- Virginia5 studier
- Washington4 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RekruttererFase 2
Alder 18 til 120 · Alle køn · Opdateret 2. okt. 2026 · NCT06406465Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
RekruttererFase 1
Alder 18 til 120 · Alle køn · Opdateret 2. okt. 2026 · NCT07509034Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
RekruttererObservationsstudie
Alder 18 til 120 · Alle køn · Opdateret 24. sep. 2026 · NCT05237934Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07278479Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07080242A Study of Armored CAR T Cells in People With Cancer
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT07783477A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT07488923A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT07129252A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 15. jul. 2026 · NCT05652686Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
RekruttererFase 1/2
Alder 18 til 99 · Alle køn · Opdateret 13. jul. 2026 · NCT05000294A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 9. jul. 2026 · NCT07174583A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
RekruttererFase 1
Alder 18 til 120 · Alle køn · Opdateret 15. jun. 2026 · NCT06041516A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 27. maj 2026 · NCT03093116SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. apr. 2026 · NCT06889493A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. dec. 2025 · NCT06943521Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.